{
  "id": 866509,
  "title": "Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial",
  "url": "https://urgent.news/2026/08/14/quantum-biopharma-strengthens-equity-and-liquidity-in-q2-2026-as-fda",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-14T11:03:24.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/quantum-biopharma-strengthens-equity-and-liquidity-in-q2-2026-as-fda-approves-lucid-ms-for-pivotal-phase-2-clinical-trial"
  },
  "original_language": "en",
  "account": null,
  "summary": "TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company”), has reported its financial and operational results for the second quarter of 2026, ended June 30, 2026. As of June 30, 2026, the Company’s combined cash and cash equivalents, and digital assets, totaled approximately US$9.5 […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}